Healthcare

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent…

2 months ago

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

BERKELEY HEIGHTS, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

2 months ago

BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug

NEW YORK, Oct. 23, 2025 /PRNewswire/ -- BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery…

2 months ago

LICORbio Strengthens Global Research Engagement With Bioz Prime Badges and Bioz Content Hub

PALO ALTO, CA / ACCESS Newswire / October 23, 2025 / Bioz, Inc., the industry-standard AI citation solution built to…

2 months ago

MGI Tech partners with Eva Holding Group to enhance the accuracy of disease monitoring

SÃO PAULO, Oct. 22, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing essential tools and technologies…

2 months ago

Did DEA’s Anne Milgram Get Caught in Her Own Marijuana Criminal Algorithms?

"The ex-New Jersey Attorney General and former DEA Administrator promised to modernize justice through data. Instead, under her watch, illegal…

2 months ago

CORRECTION: MDaudit Spotlights the Vital Role of Health Information Professionals in Today’s Evolving Healthcare Landscape

The following is a corrected version of the Oct. 21, 2025, press release, MDaudit Spotlights the Vital Role of Health…

2 months ago

Lightfully Behavioral Health Expands Access to Specialized Schizoaffective Disorder Treatment Across Full Continuum of Care

THOUSAND OAKS, Calif., Oct. 22, 2025 /PRNewswire/ -- Lightfully Behavioral Health has announced the expansion of its clinical services to…

2 months ago

NEUROMARK® Now with Expanded Access on UnitedHealthcare’s Medicare Advantage Policy for Posterior Nasal Nerve Ablation

Effective immediately, CPT 31242 is no longer considered experimental, removing a key barrier for ENT physicians treating chronic rhinitis.  GALWAY, Ireland, Oct.…

2 months ago

3 in 5 HIM Leaders Report No FY26 Budget Set for TEFCA Onboarding Even as EHR Vendors Light Up National Exchange

Based on a Black Book Research flash survey of 97 HIM leaders conducted at AHIMA 2025 last week. MINNEAPOLIS, MN…

2 months ago